Market Access News | pharmaphorum

News

Lilly's migraine drug gets key cluster headache approval

The FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving the calcitonin gene-related peptide (CGRP) antibody a key poin

News

bluebird claims first approval for gene therapy Zynteglo in ...

bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its ex vivo gene therapy for the rare blood disorder beta thalassaemia.

News

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements from the EMA.

News

Amarin’s Vascepa gets priority review for cardiovascular lab...

Amarin’s cardio drug Vascepa (icosapent ethyl) has been granted Priority Review designation by the FDA after trial results showed it could reduce the risk of major cardio events by up to 25

News

AZ pulls back on Inovio immuno-oncology pact

AstraZeneca has decided to trim back its 2015 alliance with Inovio Pharmaceuticals, which focused on combining the biotech’s DNA cancer vaccines with AZ’s cancer immunotherapies.

News

Bayer's Aliqopa gets speedy review for marginal zone lymphom...

The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies.

Lilly's migraine drug gets key cluster headache approval

bluebird claims first approval for gene therapy Zynteglo in ...

Mitsubishi Tanabe pulls ALS drug from EMA assessment

Amarin’s Vascepa gets priority review for cardiovascular lab...

AZ pulls back on Inovio immuno-oncology pact

Bayer's Aliqopa gets speedy review for marginal zone lymphom...

Tarsus places $800m wager on Alkeus' Stargardt therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks